SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences trades jubilantly on the bourses

09 Jun 2014 Evaluate

Nectar Lifesciences is currently trading at Rs. 33.20, up by 4.00 points or 13.70% from its previous closing of Rs. 29.20 on the BSE.

The scrip opened at Rs. 32.60 and has touched a high and low of Rs. 35.00 and Rs. 32.00 respectively. So far 683639 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 35.00 on 09-June-2014 and a 52 week low of Rs. 9.65 on 06-Aug-2013.

Last one week high and low of the scrip stood at Rs. 35.00 and Rs. 26.90 respectively. The current market cap of the company is Rs. 735.58 crore.

The promoters holding in the company stood at 44.35% while Institutions and Non-Institutions held 14.87% and 20.26% respectively.

Nectar Lifesciences’ promoters are reportedly planning to sell their entire stake in the company. Sanjiv Goyal and family are planning to sell their 44.35% stake in the company. However, the management has denied any such reports.

It is being said that in this regard, the company has appointed IDFC Investment Bank to look for buyers. As on March 31, 2014, the promoters holding in the company stood at 44.35%, while Institutions and Non-Institutions held 14.87% and 20.26% stake in the company, respectively.

Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.

 

 

Nectar Lifesciences Share Price

12.66 0.25 (2.01%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×